



OIPF

CAU1642

Dkt. 0392/25799-DB/RDK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant : Jean-Claude Bystryn
Serial No. : 10/046,880
Filed : January 15, 2002
For : ANTI-CANCER VACCINE

MAY 01 2002

Group Art Unit - 1642 TECH CENTER 1600/290

1185 Avenue of the Americas
New York, New York 10036
April 19, 2002

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

SIR:

**COMMUNICATION REQUESTING
CORRECTION OF THE OFFICIAL FILING RECEIPT**

RECEIVED
JUL 17 2002
TECH CENTER 1600/290

Applicant encloses a copy of the Official Filing Receipt issued in connection with the above-identified application (Exhibit 1). An error appears in the filing receipt. The Attorney Docket No. should read 0392/25799-DB/RDK. Also, please add New York, New York for the residence of applicant.


Correction of the filing receipt is respectfully requested. The Commissioner is hereby authorized to charge any fees which may be required in consideration of this filing and to credit any overpayment to our Deposit Account No. 03-3125.

Respectfully submitted,

Dated: April 19, 2002

By:

Robert D. Katz




Robert D. Katz
Reg. No. 30,141
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400
Attorney for Applicant



25799-03

UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED

Page 1 of 2

MAY 01 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/046,880	01/15/2002	1642	370	0392/35799-DB/RDK		9	3

Robert D. Katz
COOPER & DUNHAM LLP
1185 Avenue of the Americas
New York, NY 10036

FEB 27 2002

AP

DKT #
incurs

CONFIRMATION NO. 5017

FILING RECEIPT



OC00000007512332

Date Mailed: 02/21/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

✓ Jean-Claude Bystryn, Residence Not Provided;

COPY OF PAPERS
ORIGINALLY FILED

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 08/865,112 05/29/1997 PAT 6,338,853
WHICH IS A CIP OF 08/367,682 12/30/1994 PAT 5,635,188
WHICH IS A CON OF 08/210,243 03/18/1994 ABN
WHICH IS A CON OF 07/717,972 06/20/1991 ABN
WHICH IS A CON OF 07/485,780 02/22/1990 PAT 5,030,621
WHICH IS A CON OF 07/041,864 04/23/1987 ABN

Foreign Applications

If Required, Foreign Filing License Granted 02/21/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

RECEIVED
JUL 17 2002
TECH CENTER 1600/2900

Anti-cancer vaccine.

Preliminary Class
424

RECEIVED

MAY 01 2002
RECEIVED
TECH CENTER 1600/2900
JUL 17 2002

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

TECH CENTER 1600/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

COPY OF PAPERS
ORIGINALLY FILED
